IS3019B - Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi - Google Patents

Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi

Info

Publication number
IS3019B
IS3019B IS8825A IS8825A IS3019B IS 3019 B IS3019 B IS 3019B IS 8825 A IS8825 A IS 8825A IS 8825 A IS8825 A IS 8825A IS 3019 B IS3019 B IS 3019B
Authority
IS
Iceland
Prior art keywords
triazole
amorphous form
pyrimidine compound
new crystalline
crystalline
Prior art date
Application number
IS8825A
Other languages
English (en)
Other versions
IS8825A (is
Inventor
Martin Bohlin
Steve Cosgrove
Bo Lassen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS3019(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8825A publication Critical patent/IS8825A/is
Publication of IS3019B publication Critical patent/IS3019B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
IS8825A 2000-06-02 2009-06-02 Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi IS3019B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0013407.2A GB0013407D0 (en) 2000-06-02 2000-06-02 Forms of a chemical compound

Publications (2)

Publication Number Publication Date
IS8825A IS8825A (is) 2009-06-02
IS3019B true IS3019B (is) 2020-02-15

Family

ID=9892841

Family Applications (2)

Application Number Title Priority Date Filing Date
IS6623A IS2609B (is) 2000-06-02 2002-11-15 Ný kristölluð form efnasambands (1S-(1a, 2a, 3B(1S*, 2R*), 5B))-3-(7-((2-(2,4-díflúorófenýl)sýklóprópýl)amínó)-5-(próýlþíó)-3H-1,2,3-tríazóló(4,5-d)pýrimídín-3-ýl)-5-(2-hýdróxýetoxý)sýklópentan-1,2-díól
IS8825A IS3019B (is) 2000-06-02 2009-06-02 Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS6623A IS2609B (is) 2000-06-02 2002-11-15 Ný kristölluð form efnasambands (1S-(1a, 2a, 3B(1S*, 2R*), 5B))-3-(7-((2-(2,4-díflúorófenýl)sýklóprópýl)amínó)-5-(próýlþíó)-3H-1,2,3-tríazóló(4,5-d)pýrimídín-3-ýl)-5-(2-hýdróxýetoxý)sýklópentan-1,2-díól

Country Status (36)

Country Link
US (3) US20030181469A1 (is)
EP (3) EP1493745B2 (is)
JP (3) JP5036947B2 (is)
KR (1) KR100781864B1 (is)
CN (2) CN1817883B (is)
AR (2) AR032335A1 (is)
AT (2) ATE320430T1 (is)
AU (4) AU6287401A (is)
BG (3) BG65837B1 (is)
BR (1) BR0111328A (is)
CA (1) CA2408596C (is)
CY (1) CY1113047T1 (is)
CZ (2) CZ304347B6 (is)
DE (1) DE60117972T2 (is)
DK (2) DK1289992T3 (is)
EE (1) EE05222B1 (is)
ES (2) ES2259031T3 (is)
GB (1) GB0013407D0 (is)
HK (2) HK1052347B (is)
HU (2) HU230471B1 (is)
IL (4) IL152777A0 (is)
IS (2) IS2609B (is)
MX (1) MXPA02011795A (is)
MY (2) MY148652A (is)
NO (3) NO323780B1 (is)
NZ (1) NZ522638A (is)
PH (1) PH12011000127A1 (is)
PL (2) PL359172A1 (is)
PT (2) PT1289992E (is)
RU (3) RU2325391C2 (is)
SG (1) SG135965A1 (is)
SI (2) SI1493745T1 (is)
SK (1) SK287817B6 (is)
UA (1) UA73181C2 (is)
WO (1) WO2001092262A1 (is)
ZA (1) ZA200209324B (is)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
JP4298212B2 (ja) * 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
US20080045548A1 (en) * 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
JP2010508350A (ja) * 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
CN103071154A (zh) * 2007-04-13 2013-05-01 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
KR101669297B1 (ko) 2008-09-09 2016-10-25 아스트라제네카 아베 [1Ｓ-[1-알파,2-알파,3-베타(1Ｓ*,2Ｒ*),5-베타]]-3-[7-[2-(3,4-디플루오로페닐)-사이클로프로필아미노]-5-(프로필티오)-3Ｈ-1,2,3-트리아졸로[4,5-ｄ]피리미딘-3-일]-5-(2-하이드록시에톡시)사이클로펜탄-1,2-디올의 제조 방법 및 그 중간체
US8802850B2 (en) 2009-07-27 2014-08-12 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of P2Y12 receptor
WO2011067571A1 (en) * 2009-12-03 2011-06-09 Astrazeneca Ab Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor
WO2011076749A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
CZ2011229A3 (cs) 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
CN103764149A (zh) 2011-06-01 2014-04-30 阿斯利康(瑞典)有限公司 新型替卡格雷共晶
CN104039792A (zh) * 2011-11-30 2014-09-10 阿特维斯集团公司 替格瑞洛的新结晶形式及其制备方法
US9233966B2 (en) 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2014000719A1 (en) * 2012-06-29 2014-01-03 Zentiva, K.S. Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
CA2877541C (en) 2012-07-04 2020-06-30 Lek Pharmaceuticals D.D. Ticagrelor adducts with divalent metal salts
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
CN103772393B (zh) * 2012-10-18 2017-08-04 博瑞生物医药（苏州）股份有限公司 替卡格雷的晶型及其制备方法
WO2014083139A1 (en) * 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN103848836B (zh) * 2012-12-07 2016-08-03 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物及其制备方法
WO2014118808A2 (en) * 2013-02-04 2014-08-07 Hetero Research Foundation Ticagrelor solid dispersion
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
WO2014155389A2 (en) * 2013-03-25 2014-10-02 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
CN104098570A (zh) * 2013-04-07 2014-10-15 杭州领业医药科技有限公司 替卡格雷晶型及其制备方法和用途
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
CN104098553B (zh) * 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
CA2913326A1 (en) 2013-05-29 2014-12-04 Ratiopharm Gmbh Solid pharmaceutical dosage form
CN104211704B (zh) * 2013-06-03 2017-08-25 杭州领业医药科技有限公司 结晶形态的三唑[4,5‑d]嘧啶化合物及其制备方法和用途
EP3004113A2 (en) * 2013-06-04 2016-04-13 Dr. Reddy's Laboratories Ltd. Preparation of ticagrelor
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) * 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CN104341423B (zh) * 2013-08-02 2017-03-01 上海京新生物医药有限公司 替格瑞洛的一水合物及其制备方法与在制药中的应用
CN104370912A (zh) * 2013-08-13 2015-02-25 开原亨泰制药股份有限公司 替卡格雷多晶型体及其制备方法
IN2013CH04023A (is) * 2013-09-10 2015-08-07 Laurus Labs Pvt Ltd
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104650085A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物化合物
CN103601726B (zh) * 2013-12-02 2016-09-28 浙江大学 两种替格瑞洛药物共晶及其制备方法
CN104710425B (zh) * 2013-12-16 2019-06-14 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛新结晶及其制备方法
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
WO2015162537A1 (en) * 2014-04-23 2015-10-29 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN105315282B (zh) * 2014-07-15 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷无定型的方法
WO2016016907A1 (en) * 2014-08-01 2016-02-04 Msn Laboratories Private Limited Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol
WO2016024225A1 (en) * 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Limited Stable amorphous ticagrelor and a process for its preparation
CN104193747B (zh) * 2014-08-12 2016-05-11 许彩霞 替卡格雷无定形的制备
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105968113B (zh) * 2015-03-12 2019-06-07 四川海思科制药有限公司 一种三唑并嘧啶衍生物及其应用
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
US20190002471A1 (en) * 2016-01-05 2019-01-03 Amneal Pharmaceuticals Company Gmbh Crystalline Form Of Ticagrelor
MA44720A (fr) * 2016-04-21 2019-02-27 Astrazeneca Ab Comprimés à désintégration orale
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
ES2731658T3 (es) * 2016-09-09 2019-11-18 Univ Liege Derivados triazolo(4,5-d)pirimidina para uso en la prevención y tratamiento de infección bacteriana
KR101916956B1 (ko) 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
WO2018178997A1 (en) 2017-03-31 2018-10-04 Natco Pharma Limited Novel crystalline form of ticagrelor
WO2019127294A1 (zh) * 2017-12-29 2019-07-04 浙江天宇药业股份有限公司 一种纯化替格瑞洛的方法
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
EA202190328A1 (ru) 2018-07-27 2021-07-01 КРКА, д.д., НОВО МЕСТО Фармацевтическая композиция, содержащая тикагрелор
CN110194771A (zh) * 2019-05-08 2019-09-03 北京济美堂医药研究有限公司 一种替格瑞洛药用ii晶型的制备方法
CN114634489B (zh) * 2022-04-19 2023-07-04 奎马特里克斯有限公司 结晶形式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
WO1997003084A1 (en) 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
ATE213245T1 (de) * 1996-12-20 2002-02-15 Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
WO1999005150A1 (en) * 1997-07-25 1999-02-04 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound

Also Published As

Publication number Publication date
EP1493745A1 (en) 2005-01-05
IL202582A0 (en) 2010-06-30
MY140674A (en) 2010-01-15
NZ522638A (en) 2004-06-25
MXPA02011795A (es) 2003-04-10
NO20025756D0 (no) 2002-11-29
EE200200665A (et) 2004-06-15
CN1247583C (zh) 2006-03-29
JP2014129423A (ja) 2014-07-10
BG66332B1 (bg) 2013-06-28
NO333289B1 (no) 2013-04-29
BR0111328A (pt) 2003-06-10
NO323780B1 (no) 2007-07-02
RU2010150799A (ru) 2012-06-20
EP1493745B1 (en) 2012-04-25
AU2001262874B2 (en) 2007-03-22
US20030181469A1 (en) 2003-09-25
AU2007200958A1 (en) 2007-03-29
EP1493745B2 (en) 2021-05-19
RU2418802C2 (ru) 2011-05-20
SK16852002A3 (sk) 2003-08-05
EE05222B1 (et) 2009-10-15
IS8825A (is) 2009-06-02
ES2259031T3 (es) 2006-09-16
PT1493745E (pt) 2012-06-28
IL152777A0 (en) 2003-06-24
IS2609B (is) 2010-04-15
PL359172A1 (en) 2004-08-23
EP2292622A1 (en) 2011-03-09
PT1289992E (pt) 2006-07-31
BG65837B1 (bg) 2010-02-26
CY1113047T1 (el) 2016-04-13
AU2007200958B2 (en) 2010-10-07
CN1817883A (zh) 2006-08-16
MY148652A (en) 2013-05-15
US20070173518A1 (en) 2007-07-26
BG110440A (bg) 2010-03-31
SG135965A1 (en) 2007-10-29
IS6623A (is) 2002-11-15
HUP1300386A2 (en) 2003-10-28
NO20120595L (no) 2003-01-24
HK1052347B (zh) 2006-09-08
US7265124B2 (en) 2007-09-04
JP5036947B2 (ja) 2012-09-26
ES2384708T3 (es) 2012-07-11
PH12011000127A1 (en) 2016-08-31
BG107331A (bg) 2003-07-31
WO2001092262A1 (en) 2001-12-06
DE60117972T2 (de) 2006-11-23
DE60117972D1 (de) 2006-05-11
GB0013407D0 (en) 2000-07-26
IL187482A (en) 2010-06-16
CZ307468B6 (cs) 2018-09-26
NO332306B1 (no) 2012-08-20
JP2012149093A (ja) 2012-08-09
HUP0302284A3 (en) 2007-05-29
ATE320430T1 (de) 2006-04-15
EP1289992B1 (en) 2006-03-15
HUP0302284A2 (hu) 2003-10-28
NO20071547L (no) 2003-01-24
AU2010257449B2 (en) 2012-03-22
JP2003535092A (ja) 2003-11-25
PL392882A1 (pl) 2011-03-14
US20070293513A1 (en) 2007-12-20
NO20025756L (no) 2003-01-24
KR100781864B1 (ko) 2007-12-05
KR20030007829A (ko) 2003-01-23
CZ304347B6 (cs) 2014-03-19
BG111017A (bg) 2011-12-30
DK1289992T3 (da) 2006-07-03
HU229374B1 (en) 2013-11-28
RU2005127356A (ru) 2007-03-10
IL202582A (en) 2012-12-31
HK1073101A1 (en) 2005-09-23
CN1817883B (zh) 2011-10-05
SI1289992T1 (sl) 2006-08-31
JP5684192B2 (ja) 2015-03-11
AR068086A2 (es) 2009-11-04
CA2408596C (en) 2010-12-21
EP1289992A1 (en) 2003-03-12
AU2010257449A1 (en) 2011-01-20
SK287817B6 (sk) 2011-11-04
CZ20120293A3 (is) 2003-07-16
IL152777A (en) 2008-11-26
RU2325391C2 (ru) 2008-05-27
DK1493745T3 (da) 2012-07-16
SI1493745T1 (sl) 2012-08-31
ZA200209324B (en) 2004-02-16
AR032335A1 (es) 2003-11-05
ATE555115T1 (de) 2012-05-15
HK1052347A1 (en) 2003-09-11
CN1432018A (zh) 2003-07-23
AU6287401A (en) 2001-12-11
CA2408596A1 (en) 2001-12-06
HU230471B1 (hu) 2016-07-28
UA73181C2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
IS3019B (is) Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi
IS7007A (is) Kristallaform af asiþrómýsíni
CY2015035I2 (el) Ενωσεις πυριμιδινης
NO20025719L (no) Nye triazolpyrimidinforbindelser
NO20024127L (no) Pyrimidin-forbindelser
DK1169314T3 (da) Krystallinsk base af citalopram
PT1135391E (pt) Novos compostos de tiazolo(4,5-d)pirimidina
DK1056444T3 (da) Stabile formede partikler af krystallinske organiske forbindelser
NO20026001D0 (no) 3'-promedikamenter av 2'-deoksy-<Beta>-L-nukleosider
DK1149090T3 (da) Ny krystallinsk form af kaliumsalt af (S)-omeprazol
IS5640A (is) Ný kristalla form af Bensímídazól efnasambandi gegn veirum
DK1107980T3 (da) Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
PT1150960E (pt) Formas cristalinas polimorficas do celecoxib
DK1280803T3 (da) Krystallinsk form II af cabergolin
IS6215A (is) Að mestu leyti kristallað form af melagatrani
IS5821A (is) Kristalluð form af ósanetant
HUP0302675A3 (en) New crystalline modifications of lopinavir
NO20030416L (no) Krystallinsk terapeutisk forbindelse
SE0001422D0 (sv) Crystalline form
SE0001187D0 (sv) Crystalline form
SE9904417D0 (sv) Crystalline form
HK1045948A1 (zh) 奧美拉唑的新結晶形式